コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tential mediator of angiogenesis through the A2B receptor.
2 eptor other than A1, A2A or A3, possibly the A2B receptor.
3 cutely isolated astrocytes is coupled to the A2B receptor.
4 t the effect is likely to be mediated by the A2b receptor.
5 olving adenosine signaling via the adenosine A2b receptor.
6 receptors and HMEC-1 preferentially express A2B receptors.
7 xanthine 3 was >13-fold more potent at human A2B receptors.
8 a pA2 value of 8.0 but was not selective for A2B receptors.
9 d A3 receptors, retained moderate potency at A2B receptors.
10 c fibroblast proliferation via activation of A2B receptors.
11 A2A receptors and suggested a major role for A2B receptors.
12 euromodulator adenosine acting on astrocytic A2B receptors.
13 which was prevented by blockade of adenosine A2B receptors.
14 message and protein expression of A(2A) and A(2B) receptor.
15 xy derivative 9 was moderately selective for A(2B) receptors.
16 and A(2A) receptors and at recombinant human A(2B) receptors.
17 enosine T1 is mediated through the A(2A) and A(2B) receptors, (2) adenosine myocardial perfusion rese
18 n contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by
20 ed adenosine functions through the adenosine A(2B) receptor (A(2B)R) to activate the PI3K/AKT signali
21 logical approaches, we showed that adenosine A(2B) receptor (A(2B)R)-mediated induction of 2,3-diphos
24 y of p73 to upregulate the expression of the A2B receptor, a recently characterized p53 target that e
31 ular permeability occurred through adenosine A2B receptor activation and was accompanied by a paralle
34 ed ecto-5'-nucleotidase (CD73) and adenosine A(2B) receptor (ADORA2B) in the placentas of PE mouse mo
35 roarray analysis revealed that the adenosine A2B receptor (AdoRA2B) is selectively up-regulated by hy
36 signaling through the erythrocyte adenosine A2B receptor (ADORA2B) promotes O2 release to counteract
40 hese results suggest that the development of A(2B) receptor agonists to induce vasodilatation in the
44 s evidence of anti-inflammatory functions of A(2B) receptors and it was suggested that antagonists wi
45 inflammatory role of adenosine signaling via A(2B) receptors and the anti-inflammatory actions of A(2
46 ing pathway: both treatments act through the A2b receptor and specifically activate the Epac1/RapGef3
47 was impaired, with a lower expression of the A2B receptor and the cAMP-response element binding prote
48 reduces bladder contractility by activating A2B receptors and large-conductance calcium-activated po
49 ol-induced hepatic steatosis via both A1 and A2B receptors and suggest that targeting adenosine recep
50 /IL3 signaling, is mediated by the adenosine A(2B) receptor, and can be pharmacologically reversed.
51 human mast cell line HMC-1 expresses A2A and A2B receptors, and that both receptors activate adenylat
52 ation of intracellular Ca(2+) inhibited both A(2B) receptor- and ionomycin-dependent IL-4 secretion.
55 ne mimicked the effect of MTX, and adenosine A2b receptor antagonist (3,7-dimethyl-1-propargylxanthin
57 effect of NECA was reversed by the selective A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-
58 ar accumulation, which were inhibited by the A2B receptor antagonist PSB603 [(8-[4-[4-((4-chlorophenz
59 2A receptor antagonist), but not by MRS1754 (A2B receptor antagonist), and it was mimicked by the A2A
61 mately 50% with combined adenosine A(2a) and A(2b) receptor antagonists and completely abolished by a
64 tial therapeutic implications given that A2A/A2B receptor antagonists have already entered clinical t
67 together, these data indicate that A(2A) and A(2B) receptors are regionally selective in their regula
69 enylate cyclase via Gs-protein but that only A2B receptors are also coupled to phospholipase C via Gq
70 al cancer (DCC), neogenin, and the adenosine A2b receptor] are expressed by the fetal mucosal epithel
71 adenosine receptor knockout mice identified A(2B) receptor as the mediator of adenosine effects on D
74 the 3-position favored affinity at the human A2B receptor, as indicated by 1-allyl-3-methyl-8-phenylx
76 atory effect of adenosine required primarily A(2B) receptors because the nonselective adenosine recep
77 on IL-10 production was mediated through the A(2B) receptor, because the order of potency of selectiv
80 a treatment also increased the expression of A(2B) receptors, but decreased expression of A(2A) recep
81 a luciferase reporter in HMEC-1 showed that A2B receptors, but not A1, A2A, or A3, activated IL-8 an
82 athophysiological conditions, the purinergic A2b receptor can regulate cell motility, but the underly
83 er ovary cells stably transfected with human A2B receptor cDNA, inhibition of agonist-induced cyclic
85 ective antagonists of both adenosine A2A and A2B receptors, consistent with ligation of these recepto
89 nuclear factor of activated T cells, because A(2B) receptor-dependent IL-4 secretion was blocked with
92 G(s)-linked pathways also play a role in the A(2B) receptor-dependent stimulation of IL-4 secretion;
93 ntracellular signaling, we demonstrated that A2B receptor-dependent accumulation of JunB protein and
94 PK pathways are essential steps in adenosine A2B receptor-dependent stimulation of IL-8 production in
95 s, our data suggest an important role of the A2B receptor-dependent upregulation of JunB in VEGF prod
99 hrough activation of PMN adenosine A(2A) and A(2B) receptors, functions as an antiadhesive signal for
104 To better understand the regulation of the A2b receptor in intestinal epithelia, we studied the eff
105 report increased expression of the adenosine A2b receptor in meniscus cells after stimulation at the
107 ng conditional deletion of the gene encoding A2B receptors in astrocytes showed that adenosine-mediat
115 otective effects of HPC are negated when the A2B receptor is nonfunctional, the hypoxia-->adenosine--
116 enal perfusion by endothelial cell adenosine A2B receptors is antagonized by adenosine reuptake into
119 receptor knockout), A(2B)AR(-/-) (adenosine A(2B) receptor knockout), A(3)AR(-/-) (adenosine A(3) re
120 f Sca-1(+)CD31(-) cells generated from WT or A2B receptor knockout (A2BKO) mice or the same volume of
121 s much milder than we previously reported in A2b receptor knockout (A2bKO) mice, suggesting compensat
122 s bladder activity through the activation of A2B receptors, linking acute hypoxia to bladder relaxati
124 , CAF-CD73 expression is enhanced via an ADO-A(2B) receptor-mediated feedforward circuit triggered by
125 3-yl)maleimide (Ro-32-0432) had no effect on A(2B) receptor-mediated IL-4 secretion but inhibited pho
126 ther apical or basolateral adenosine induces A2b receptor-mediated increase in IL-6 secretion, which
127 indings demonstrate that inosine acts via an A2B receptor-mediated pathway that impinges on specific
130 n experiments with A(2A)AR(-/-) or adenosine A(2B) receptor(-/-) mice, the effect of AMO injection wa
131 ribozyme that would specifically cleave the A2B receptor mRNA and examine its effect on retinal angi
132 the plasmid expressing the ribozyme reduced A2B receptor mRNA levels by 45+/-4.8% (P=5.1x10(-5)).
133 lls were transfected with these plasmids and A2B receptor mRNA levels were determined by quantitative
134 Ribozymes specific for the mouse and human A2B receptor mRNAs were designed and cloned in expressio
136 unsubstituted anilide 12 had a K(i) value at A(2B) receptors of 1.48 nM but was only moderately selec
137 s of adenosine in tumors activates A(2A) and A(2B) receptors on immune cells and inhibits their abili
138 row chimeras revealed that it is the lack of A(2B) receptors on nonhematopoietic cells that is primar
141 is nonfunctional, the hypoxia-->adenosine-->A2B receptor pathway plays a critical role in the preven
145 as recently been proposed that the adenosine A2B receptor plays a crucial role in skeletal muscle ene
149 we demonstrate that genetic ablation of the A(2B) receptor protein has two distinct effects on BMMCs
152 by this process activates surface adenosine A(2B) receptors, results in endothelial junctional reorg
155 ituted in the 1-, 3-, 7-, and 8-positions as A2B receptor-selective antagonists have been identified.
156 ogenous adenosine deaminase, suggesting that A(2b) receptors sense endogenous adenosine within the AS
157 in expression or membrane recruitment of the A2b receptor, shown to be essential for its function.
158 actors, we hypothesized that ablation of the A2B receptor signaling in these cells would reduce their
160 adenosine, which in turn promotes adenosine-A2b receptor signaling to relax bladder smooth muscle (B
161 sine agonist, the desensitization of A2a and A2b receptor-stimulated adenylyl cyclase in dominant neg
162 lls, the rates of desensitization of A2a and A2b receptor-stimulated adenylyl cyclase were markedly s
167 oalkylacyl derivatives demonstrated that for A2B receptors the optimal chain length occurs with three
168 signal in a paracrine faction ciliated cell A(2b) receptors to activate ion/water secretion and appr
169 racellular pathways that link stimulation of A(2B) receptors to IL-4 up-regulation in HMC-1 mast cell
171 ses (PDEs) confines cAMP generated by apical A2B receptors to a microdomain that includes the CFTR ch
172 product of ATP hydrolysis by ENTPD, acts via A2B receptors to counterbalance the pro-fibrotic respons
178 current study, we tested the hypothesis that A2B receptors upregulate JunB, which can contribute to s
179 400-, 245-, and 123-fold selective for human A(2B) receptors versus human A(1)/A(2A)/A(3) receptors,
180 receptor muscarinic 3), purinergic P2X1, and A2b receptors was unchanged, whereas P2Y12 receptor was
181 ous series, maintaining the potency at human A(2B) receptor, was achieved, as exemplified by the 8-[3
183 king ecto-5'-nucleotidase or adenosine A1 or A2B receptors were protected from developing fatty liver
184 naling is achieved through adenosine A2A and A2B receptors, which are Gs coupled, and their activatio
185 ides with acrylic acid decreased affinity at A(2B) receptors while increasing affinity at A(1) recept
186 osine A2A receptor; 12-fold versus adenosine A2B receptor) with improved oral efficacy in the rat diu